Compare Dropbox Inc (DBX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Recursion Pharmaceuticals Inc — how do they compare? Dropbox Inc trades at $34.36 (market cap $7.42B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Dropbox Inc is far larger — about 3.5× Recursion Pharmaceuticals Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DBX | RXRX | |
|---|---|---|
Market Cap | $7.42B | $2.14B |
Volume | 3,061,580 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $37.74 | $6.79 |
52-Week Low | $22.06 | $2.84 |
Typical Hold Time | 97 Days | 23 Days |
Enterprise Value | $10.29B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.14, up 3.2% today, with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable near $2.5B annually, while net income margin improved to 20.16% in 2025. However, negative shareholder equity and high debt levels pose fundamental concerns, and recent insider selling and a mixed analyst consensus indicate cautious sentiment.
The outlook is mixed: strong profitability and cash flow support valuation, but stagnant growth and insider disposals suggest limited upside. Key risks include competitive pressure in cloud storage and execution challenges. Investors should weigh solid fundamentals against sentiment headwinds.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
